Pfizer reports topline data from SigVie-002 study for NSCLC

​Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with previously treated, locally advanced or metastatic non-squamous NSCLC.

The post Pfizer reports topline data from SigVie-002 study for NSCLC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.